# Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 Balance Sheet

- Company: Mirum Pharmaceuticals, Inc. (MIRM)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-05, accession number 0001759425-26-000045
- Page: https://plicit.ai/financials/mirm/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/mirm-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 1,044,981,000 US dollars
- **Current assets**: 636,310,000 US dollars
- **Non-current assets**: 408,671,000 US dollars
- **Liabilities**: 1,055,403,000 US dollars
- **Current liabilities**: 222,788,000 US dollars
- **Non-current liabilities**: 832,615,000 US dollars
- **Equity**: negative 10,422,000 US dollars
- **Cash and cash equivalents**: 330,728,000 US dollars
- **Accounts receivable**: 145,360,000 US dollars
- **Short-term investments**: 107,563,000 US dollars
- **Prepaid expenses and other current assets**: 26,890,000 US dollars
- **Inventory**: 25,769,000 US dollars
- **Intangible assets, net**: 247,388,000 US dollars
- **Long-term investments**: 123,030,000 US dollars
- **Other assets**: 22,244,000 US dollars
- **Operating lease right-of-use assets**: 12,024,000 US dollars
- **Property and equipment, net**: 2,251,000 US dollars
- **Restricted cash**: 1,734,000 US dollars
- **Accrued expenses and other current liabilities**: 174,561,000 US dollars
- **Holdback liabilities, current**: 24,800,000 US dollars
- **Accounts payable**: 23,427,000 US dollars
- **Convertible notes payable, net, noncurrent**: 750,079,000 US dollars
- **Holdback liabilities, noncurrent**: 61,154,000 US dollars
- **Other liabilities**: 10,917,000 US dollars
- **Operating lease liabilities, noncurrent**: 10,465,000 US dollars
- **Additional paid-in capital**: 1,515,172,000 US dollars
- **Common stock, $0.0001 par value; 200,000,000 shares authorized; 64,754,699 and 51,896,391 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively**: 6,000 US dollars
- **Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of June 30, 2026 and December 31, 2025**: 0 US dollars
- **Accumulated deficit**: negative 1,524,926,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 674,000 US dollars

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.